Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;23(3):102.
doi: 10.3892/ol.2022.13222. Epub 2022 Jan 31.

Preferential radiosensitization to glioblastoma cancer stem cell-like cells by a Hsp90 inhibitor, N-vinylpyrrolidone-AUY922

Affiliations

Preferential radiosensitization to glioblastoma cancer stem cell-like cells by a Hsp90 inhibitor, N-vinylpyrrolidone-AUY922

Toshiaki Tani et al. Oncol Lett. 2022 Mar.

Abstract

The present study examined the radiosensitization induced by a heat shock protein 90 inhibitor, N-vinylpyrrolidone (NVP)-AUY922, in CD133-positive cells in a hypoxic area of T98G spheroids. CD133-positive cells that are induced in the hypoxic microenvironment of spheroids have previously been reported to exhibit cancer stem cell-like properties. The present study used CD133-positive cells from a glioblastoma cell line (T98G) as cancer stem cell-like cells. CD133-positive and negative cells were sorted from T98G spheroids using fluorescence-activated cell sorting and used for colony formation assay. Colony formation assay results indicated that NVP-AUY922 enhanced radiosensitivity more strongly in CD133-positive cells compared with CD133-negative cells. This result showed that NVP-AUY922 was a preferential radiosensitization candidate targeting glioblastoma cancer stem cells. The mechanisms underlying radiosensitization by NVP-AUY922 are discussed in relation to the properties of cancer stem cells. Overall, HIF-1α inhibition by NVP-AUY922 may induce higher sensitization of cancer stem cells to radiation.

Keywords: N-vinylpyrrolidone-AUY922; cancer stem cell; glioblastoma; heat shock protein 90 inhibitor; radiosensitization.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1.
Figure 1.
A schema on significance of CD-133 positive cells. The figure shows cancer stem cell-like properties in CD133-positive cells in T98G cell line-derived spheroids.
Figure 2.
Figure 2.
Images of CD133/HIF-1α immunofluorescent double staining. Monolayer cultured cells staining for (A) CD133, (B) HIF-1α and (C) CD133/HIF-1α; spheroid sections on day 10 after cell seeding for (D) CD133 (red-colored), (E) HIF-1α (green-colored) and (F) CD133/HIF-1α (yellow-colored). Images of CD133/nestin immunofluorescence double staining: Monolayer cultured cells staining for (G) CD133, (H) nestin and (I) CD133/nestin; spheroid sections on day 10 after cell seeding for (J) CD133 (red-colored), (K) nestin (green-colored) and (L) CD133/nestin (yellow-colored). HIF, hypoxia-inducible factor-1α.
Figure 3.
Figure 3.
Gating of CD133-positive and CD133-negative cells. Histograms on PE (labeled to CD133 antibody) signals of (A) monolayer-cultured cells and (B) spheroid-cultured cells. Cell distributions based on PE and 7-AAD signals from (C) monolayer-cultured cells and (D) spheroid-cultured cells. Spheroid or monolayer CD133-positive cells (red-colored) and spheroid CD133-negative cells (blue-colored) were sorted from the gating shown in (C and D), respectively. The gating was set on the basis of microscopic observation of PE signals in living cells (7-AAD-negative cells). 7-AAD, 7-aminoactinomycin D.
Figure 4.
Figure 4.
Surviving fractions of SCPCs and SCNCs. SCPCs (CD133+; black columns) and SCNCs (CD133; white columns) sorted from T98G spheroids were irradiated with X-rays, treated with N-vinylpyrrolidone-AUY922 alone or combined with X-rays. All plots represent the means and standard deviations of at least three independent experiments. *P<0.01 (Tukey's HSD test); #P<0.01 (Student's t-test). SCPCs, spheroid CD133-positive cells; SCNCs, spheroid CD133-negative cells.

References

    1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–466. doi: 10.1016/S1470-2045(09)70025-7. - DOI - PubMed
    1. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401. doi: 10.1038/nature03128. - DOI - PubMed
    1. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Binger DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–760. doi: 10.1038/nature05236. - DOI - PubMed
    1. Beier D, Schulz JB, Beier CP. Chemoresistance of glioblastoma cancer stem cells-much more complex than expected. Mol Cancer. 2011;10:128. doi: 10.1186/1476-4598-10-128. - DOI - PMC - PubMed
    1. Mannino M, Chalmers AJ. Radioresistance of glioma stem cells: Intrinsic characteristic or property of the ‘microenvironment-stem cell unit’? Mol Oncol. 2011;5:374–386. doi: 10.1016/j.molonc.2011.05.001. - DOI - PMC - PubMed